3D 세포배양 시장 규모, 점유율과 동향 분석 보고서 : 기술별, 용도별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

3D Cell Culture Market Summary

The global 3D cell culture market size was estimated at USD 1.26 billion in 2025 and is projected to reach USD 2.27 billion by 2033, growing at a CAGR of 7.84% from 2026 to 2033. The market's growth can be attributed to the rising efforts to develop potential alternatives to animal-based testing and the availability of funding programs for research.

Moreover, other factors anticipated to fuel market growth over the projected period are consistent efforts in R&D activities by biopharmaceutical companies for drug development & discovery and emphasis on the adoption of 3D cell cultures in cancer research.

Animal models are largely used in cellular-based studies to study various diseases' outlook. However, they carry several demerits, such as a lack of response accuracy, differences in response from different species, etc. Thus, to manage these issues, various government organizations are involved in promoting alternative ways for drug development.

Global 3D Cell Culture Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global 3D cell culture market report based on technology, application, end use, and region:

• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• Scaffold Based
  • Hydrogels
  • Polymeric Scaffolds
  • Micropatterned Surface Microplates
  • Nanofiber Base Scaffolds
• Scaffold Free
  • Hanging Drop Microplates
  • Spheroid Microplates with ULA Coating
  • Magnetic Levitation
• Bioreactors
• Microfluidics
• Bioprinting
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Cancer Research
• Stem Cell Research & Tissue Engineering
• Drug Development & Toxicity Testing
• Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Biotechnology and Pharmaceutical Companies
• Academic & Research Institutes
• Hospitals
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Technology Segment
  • 1.1.2. Application Segment
  • 1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis:
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for organ transplantation & tissue engineering
    • 3.2.1.2. Technological advancements in scaffold free technology
    • 3.2.1.3. Rise in investments and R&D funding for cell-based research
    • 3.2.1.4. Increasing focus on developing alternative to animal testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost associated with implementation
    • 3.2.2.2. Lack of compatibility and consistency
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Technology Business Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global 3D Cell Culture Market Technology Movement Analysis
• 4.3. Global 3D Cell Culture Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 4.4. Scaffold Based
  • 4.4.1. Scaffold based market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Hydrogels
    • 4.4.2.1. Hydrogels market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Polymeric Scaffolds
    • 4.4.3.1. Polymeric scaffolds market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Micropatterned Surface Microplates
    • 4.4.4.1. Micropatterned surface microplates market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Nanofiber Based Scaffolds
    • 4.4.5.1. Nanofiber based scaffolds market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Scaffold Free
  • 4.5.1. Scaffold free market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Hanging Drop Microplates
    • 4.5.2.1. Hanging drop microplates market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Spheroid Microplates with ULA coating
    • 4.5.3.1. Spheroid microplates with ULA coating market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Magnetic Levitation
    • 4.5.4.1. Magnetic levitation market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Bioreactors
  • 4.6.1. Bioreactors market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Microfluidics
  • 4.7.1. Microfluidics market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Bioprinting
  • 4.8.1. Bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global 3D Cell Culture Market Application Movement Analysis
• 5.3. Global 3D Cell Culture Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Cancer Research
  • 5.4.1. Cancer research market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Stem Cell Research & Tissue Engineering
  • 5.5.1. Stem cell research & tissue engineering market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Drug Development & Toxicity Testing
  • 5.6.1. Drug development & toxicity testing market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global 3D Cell Culture Market End Use Movement Analysis
• 6.3. Global 3D Cell Culture Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Biotechnology & Pharmaceutical Companies
  • 6.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Hospitals
  • 6.6.1. Hospital market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico 3D Cell Culture, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway 3D Cell Culture, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea 3D Cell Culture, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina 3D Cell Culture, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE 3D Cell Culture, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait 3D Cell Culture, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. PromoCell GmbH
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Lonza
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Corning Incorporated
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Avantor, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Tecan Trading AG
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. REPROCELL Inc.
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. CN Bio Innovations Ltd.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Lena Biosciences
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives